Amgen stock gets a Neutral rating with a USD 400 target

Published on 10/06/2026 at 17:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock faces a Neutral rating from Cantor Fitzgerald at USD 400 on October 5, 2026. Q2 revenue reached USD 10.05 billion, up 10 percent year over year.

Flatlay-Anordnung mit Aktienzertifikat, ISIN-Kärtchen, Petrischale, Pipette und Antikörper-Modell auf weißem Untergrund — Amgen Inc. (ISIN US0311621009) symbolisiert dieses Flatlay mit Aktienzertifikat, ISIN-Karte und Labormaterialien, Illustration mit AI erstellt.

Amgen stock was trading at USD 404.83 on Nasdaq on October 6, 2026 at 11:31 a.m. ET, up 0.46 percent from the prior close of USD 402.98. Cantor Fitzgerald reiterated a Neutral rating with a USD 400 price target on October 5, 2026, according to Investing.com.

Analyst target stays below the stock

The USD 400 target sits below the October 6 trading price, leaving Cantor's stance close to neutral rather than directional. The firm cited commercial execution, while also pointing to reset expectations for Lp(a) after HORIZON results and positive data from Amgen's Sjogren's program, as Investing.com reported on October 5, 2026.

Consensus measures remain divided. MarketBeat listed a Hold consensus from 30 analysts, with 1 Strong Buy, 11 Buy, 15 Hold and 3 Sell ratings, alongside an average target of USD 385.25.

Q2 revenue provides the operating anchor

Amgen's Q2 2026 results give the valuation debate a firm operating reference. Total revenue reached USD 10.05 billion, up 10 percent from Q2 2025, while GAAP diluted EPS was USD 4.37 and non-GAAP diluted EPS was USD 6.29, according to TradingView.

The same Q2 report showed USD 3.489 billion in free cash flow and a 48.4 percent non-GAAP operating margin on product sales. Repatha revenue rose 37 percent to USD 953 million, while EVENITY sales increased 38 percent to USD 714 million, concentrating the growth case in established products as the pipeline develops.

Pipeline events shape the next debate

Amgen listed positive topline Phase 3 OASIZ 301 results for dazodalibep on September 22, 2026, targeting moderate-to-severe systemic Sjogren's disease, on its investor-relations page. The result adds a clinical catalyst to the commercial figures, but the October 5 analyst view shows that valuation and future trial execution remain central to the stock discussion.

Amgen's current market value was USD 218.5 billion on October 6, 2026. The share price stood 9.44 percent below its 52-week high of USD 447.03 and 40.57 percent above its 52-week low of USD 288.00, placing the stock in the upper half of its annual range.

Amgen stock holds above USD 400

Amgen stock was last at USD 404.83 on Nasdaq on October 6, 2026 at 11:31 a.m. ET, with intraday trading between USD 396.02 and USD 405.00. The operating figures, analyst target and pipeline milestones leave the USD 400 level as the clearest near-term reference for the market.